FLAME 30
Laboratory-Developed Testing: Technologies and Markets
Report Highlights
The laboratory-developed test market within the U.S. was valued at $8.1 billion in 2013 and $9.7 billion in 2014. The market is expected to reach roughly $17.7 billion in 2019, a compound annual growth rate (CAGR) of 12.7% from 2014 to 2019.
Report Includes
- Analyses of global market trends, with data from 2012, 2013 and 2014, and projections of CAGRs through 2019.
- Coverage of different types of tests including esoteric, public health, anatomic technology, genomic testing, mass spectrophotometry, and other new technologies.
- Information on the industry's structure, with focuses on reagent manufacturers, reference laboratrories, academic medical centers, trends in pricing and performance, as well as other areas.
- Relevant patent analysis, including key patents, new patents, and pending patents.
- Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities.
SCOPE OF REPORT
This report will focus on companies that rely on laboratory-developed testing for at least 10% of their revenue. This is meant to avoid focusing on companies and laboratories that only occasionally offer laboratory-developed tests to deal with unique patient needs. This report will also focus on suppliers of the analyte-specific reagents used within these laboratory-developed tests, as their contract manufacturing is a key to the successful development of these tests. While various technologies will be highlighted with relation to their use in laboratory-developed testing, we will not explore the markets for these different technologies in depth.
Analyst Credentials
Todd Graham is an experienced scientist who has worked in a variety of settings throughout the biotechnology industry for more than 10 years as a key technical resource for a variety of businesses. Among his accomplishments are coordinating the roll out of a new test for a major clinical laboratory services provider, developing pre-clinical and clinical assays in support of pharmaceuticals and medical devices, and being a key team member in developing novel technologies for molecular diagnostics.
